Selective Inhibition of 11β-Hydroxysteroid Dehydrogenase Type 1 Improves Hepatic Insulin Sensitivity in Hyperglycemic Mice Strains

Endocrinology

Volumn 144, Issue 11, 2003, Pages 4755-4762

  Alberts, Peteris ^a,b   Nilsson, Cecilia ^a   Selén, Göran ^a   Engblom, Lars O M ^a   Edling, Naimie H M ^a   Norling, Solveig ^a   Klingström, Gunnel ^a   Larsson, Catarina ^a   Forsgren, Margareta ^a   Ashkzari, Mandana ^a   Nilsson, Catrine E ^a   Fiedler, Maj ^a   Bergqvist, Elisabet ^a   Öhman, Birgitta ^a   Björkstrand, Eva ^a   Abrahmsén, Lars B ^a  

^a BIOVITRUM AB   (Sweden)

^b Biovitrum SE12 ^*  (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 11BETA HYDROXYSTEROID DEHYDROGENASE TYPE 1; 3 CHLORO 2 METHYL N [4 [2 (4 METHYL 1 PIPERAZINYL) 2 OXOETHYL] 1,3 THIAZOL 2 YL]BENZENESULFONAMIDE; 3 CHLORO 2 METHYL N [4 [2 (4 METHYL 1 PIPERAZINYL) 2 OXOETHYL] 2 THIAZOLYL]BENZENESULFONAMIDE; ANTIDIABETIC AGENT; CHOLESTEROL; FATTY ACID; GLUCOSE; INSULIN; MESSENGER RNA; NEUTRAL INSULIN; OXIDOREDUCTASE INHIBITOR; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG SELECTIVITY; DRUG TARGETING; ENZYME INHIBITION; FOOD INTAKE; GENE EXPRESSION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; LIVER; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ADIPOSE TISSUE; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; HYPERINSULINISM; INSULIN; LIVER; MALE; MICE; MICE, INBRED C57BL; OBESITY; PIPERAZINES; RNA, MESSENGER; SULFONAMIDES; THIAZOLES;

EID: 0242468543     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2003-0344     Document Type: Article

References (33)

1. Andrews RC, Walker BR 1999 Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci 96:513-523
2. DeFronzo RA 1997 Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev 5:177-269
3. Pilkis SJ, Granner DK 1992 Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis. Annu Rev Physiol 54:885-909
4. Friedman JE, Yun JS, Patel YM, McGrane MM 1993 Glucocorticoids regulate the induction of phosphoenolpyruvate carboxykinase. J Biol Chem 268:12952-12957
5. Rizza RA, Mandarino LJ, Gerich JE 1982 Cortisol-induced insulin resistance in man: impaired suppression of glucose. J Clin Endocrinol Metab 54:131-138.
6. Nieman LK, Chrousos GP, Kellner C, Spitz IM, Nisula BC, Cutler GB, Merriam GR, Bardin CW, Loriaux DL 1985 Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab 61:536-540
7. Friedman JE, Sun Y, Ishizuka T, Farrell CJ, McCormack SE, Herron LM, Hakimi P, Lechner P, Yun JS 1997 Phosphoenolpyruvate carboxykinase (GTP) gene transcription and hyperglycemia are regulated by glucocorticoids in genetically obese db/db transgenic mice. J Biol Chem 272:31475-31481
8. Nobel S, Abrahmsén L, Oppermann U 2001 Metabolic conversion as a pre-receptor control mechanism for lipophilic hormones. Eur J Biochem 268:4113-4125
9. Seckl JR, Chapman KE 1997 Medical and physiological aspects of the 11β-hydroxysteroid dehydrogenase. Eur J Biochem 249:361-364
10. Edwards CR, Stewart PM, Burt D, Brett L, McIntyre MA, Sutanto WS, de Kloet ER, Monder C 1988 Localisation of 11β-hydroxysteroid dehydrogenase: tissue specific protector of the mineralocorticoid receptor. Lancet 2:986-989
11. Funder JW, Pearce PT, Smith R, Smith AI 1988 Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 242:583-585
12. Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, Best R, Brown R, Edwards CRW, Seckl JR, Mullins JJ 1997 11β-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA 94:14924-14929
13. Morton NM, Holmes MC, Fiévet C, Staels B, Tailleux A, Mullins JJ, Seckl JR 2001 Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11β-hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem 276:41293-41300
14. Alberts P, Engblom L, Edling N, Forsgren M, Klingström G, Larsson C, Rönquist-Nii Y, Öhman B, Abrahmsén L 2002 Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 45:1528-1532
15. Barf T, Vallgårda J, Emond R, Häggström C, Kurz G, Nygren A, Larwood V, Mosialou E, Axelsson K, Olsson R, Engblom L, Edling N, Rönquist-Nii Y, Öhman B, Alberts P, Abrahmsén L 2002 Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11β-hydroxysteroid dehydrogenase type 1. J Med Chem 45:3813-3815
16. Ren JM, Marshall BA, Mueckler MM, McCaleb M, Amatruda JM, Shulman GI 1995 Overexpression of Glut4 protein in muscle increases basal and insulin-stimulated whole body glucose disposal in conscious mice. J Clin Invest 95: 429-432
17. Aoki K, Homma M, Hirano T, Oka K, Satoh S, Mukasa K, Ito S, Sekihara H 2001 mRNA and enzyme activity of hepatic 11β-hydroxysteroid dehydrogenase type 1 are elevated in C57BL/KsJ-db/db mice. Life Sci 69:2543-2549
18. Walker BR, Connacher AA, Lindsay RM, Webb DJ, Edwards 1995 Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. J Clin Endocrinol Metab 80:3155-3159.
19. Andrews RC, Rooyackers O, Walker BR 2003 Effects of the 11β-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab 88:285-291
20. Holmes MC, Kotelevtsev Y, Mullins JJ, Seckl JR 2001 Phenotypic analysis of mice bearing targeted deletions of 11β-hydroxysteroid dehydrogenases 1 and 2 genes. Mol Cell Endocrinol 171:15-20
21. Ottosson M, Vikman-Adolfsson K, Enerbäck S, Olivecrona G, Björntorp P 1994 The effects of cortisol on the regulation of lipoprotein lipase activity in human adipose tissue. J Clin Endocrinol Metab 79:820-825
22. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS 2001 A transgenic model of visceral obesity and the metabolic syndrome. Science 294:2166-2170
23. Rask E, Olsson T, Söderberg S, Andrew R, Livingstone DE, Johnson O, Walker BR 2001 Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 86:1418-1421
24. Rask E, Walker BR, Söderberg S, Livingstone DEW, Eliasson M, Johnson O, Andrew R, Olsson T 2002 Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11β-hydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol Metab 87:3330-3336
25. Kissebah AH, Vydelingum N, Murray R, Evans DJ, Hartz AJ, Kalkhoff RK, Adams PW 1982 Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 54:254-260
26. Bray GA, York DA 1979 Hypothalamic and genetic obesity in experimental animals: an autonomic and endocrine hypothesis. Physiol Rev 59:719-809
27. Livingstone DE, Jones GC, Smith K, Jamieson PM, Andrew R, Kenyon CJ, Walker BR 2000 Understanding the role of glucocorticoids in obesity: tissue-specific alterations of corticosterone metabolism in obese Zucker rats. Endocrinology 141:560-563
28. Walker BR 2000 Cortisol in insulin resistance syndromes. In: Walker M, Butler P, Rizza RA, eds. The diabetes annual. New York: Elsevier; vol 13:137-157
29. Shimomura Y, Bray GA, Lee M 1987 Adrenalectomy and steroid treatment in obese (ob/ob) and diabetic (db/db) mice. Horm Metab Res 19:295-299
30. Langley SC, York DA 1990 Effects of antiglucocorticoid RU 486 on development of obesity in obese fa/fa Zucker rats. Am J Physiol 259:R539-R544
31. Okada S, York DA, Bray GA 1992 Mifepristone (RU 486), a blocker of type II glucocorticoid and progestin receptors, reverses a dietary form of obesity. Am J Physiol 262:R1106-R1110
32. Alberts P, Engblom L, Edling N, Forsgren M, Klingström G, Larsson C, Rönquist-Nii Y, Öhman B, Abrahmsén L, The selective 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor BVT. 2733 administered orally lowers blood glucose levels in hyperglycemic KKAy, ob/ob, and db/db mice. Program of the 84th Annual Meeting of The Endocrine Society, San Francisco, CA, 2002, p 583 (Abstract P3-392)
33. Nilsson C, Abrahmsén L, Selén G, Nilsson CE, Norling S, Alberts P, Björkstrand E, Increased hepatic insulin sensitivity after treatment with the 11β-hydroxysteroid dehydrogenase 1 inhibitor BVT.2733. Proc 3rd International Workshop on Insulin Resistance, New Orleans, LA, 2003, 2773:11-12 (Abstract)